InNexus Biotechnology Inc. (TSX:IXS.V) (www.ixsbio.com), a drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced the Company has entered into a Collaboration Agreement with the National Cancer Institute (NCI) of the U.S. National Institutes of Health (NIH) to research proprietary technologies developed by InNexus.
"I look forward to working with the scientists at the NCI to study our technologies. Antibodies are the chosen drug development platform for pharmaceutical companies and DXL has been shown to enhance antibody performance. We will initially work with the NCI to enhance immunotoxins currently under study at the NCI," said Dr. Thomas Kindt, Chief Scientific Officer of InNexus. The principal investigator for the NCI will be Dr. Ira Pastan, distinguished Chair and Chief of the Laboratory of Molecular Biology, Center for Cancer Research at the NCI. Dr. Pastan established the Laboratory of Molecular Biology in 1970.
"We believe our technologies for enhancing the function of antibodies have immediate applicability to research currently underway at the NCI. We're excited to collaborate with the NCI and develop genetically engineered immunotoxins to selectively kill cancer cells," said Jeff Morhet, CEO of InNexus. "Dr. Pastan and the world-class research team, resources and facilities at the NCI are a wonderful opportunity for the InNexus team to collaborate and showcase our science and ability to build and commercialize products."
InNexus Resources
- AACR 2009 Scientific Poster on DXL625™
- DXL™ Pipeline & Programs
- Stock Quick Check
- Scientific Advisory Board
- Leadership Team
Golgi apparatus plays crucial role in enhancing T-cell function against cancer